JP2012518655A - プロトンポンプ阻害剤を含む制御放出組成物 - Google Patents

プロトンポンプ阻害剤を含む制御放出組成物 Download PDF

Info

Publication number
JP2012518655A
JP2012518655A JP2011551296A JP2011551296A JP2012518655A JP 2012518655 A JP2012518655 A JP 2012518655A JP 2011551296 A JP2011551296 A JP 2011551296A JP 2011551296 A JP2011551296 A JP 2011551296A JP 2012518655 A JP2012518655 A JP 2012518655A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
controlled release
coating
proton pump
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011551296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518655A5 (enExample
Inventor
ヴェンカテッシュ，ゴーピ
ゴセリン，マイケル
ライ，ジン−ワーン
ファビアーニ，フラヴィオ
Original Assignee
アプタリス ファーマテック インコーポレイテッド
シュトルベルク，クリスチャン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプタリス ファーマテック インコーポレイテッド, シュトルベルク，クリスチャン filed Critical アプタリス ファーマテック インコーポレイテッド
Publication of JP2012518655A publication Critical patent/JP2012518655A/ja
Publication of JP2012518655A5 publication Critical patent/JP2012518655A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011551296A 2009-02-23 2010-02-23 プロトンポンプ阻害剤を含む制御放出組成物 Ceased JP2012518655A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15450609P 2009-02-23 2009-02-23
US61/154,506 2009-02-23
PCT/US2010/025067 WO2010096814A1 (en) 2009-02-23 2010-02-23 Controlled-release compositions comprising a proton pump inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016073927A Division JP2016164170A (ja) 2009-02-23 2016-04-01 プロトンポンプ阻害剤を含む制御放出組成物

Publications (2)

Publication Number Publication Date
JP2012518655A true JP2012518655A (ja) 2012-08-16
JP2012518655A5 JP2012518655A5 (enExample) 2013-04-11

Family

ID=42634252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011551296A Ceased JP2012518655A (ja) 2009-02-23 2010-02-23 プロトンポンプ阻害剤を含む制御放出組成物
JP2016073927A Pending JP2016164170A (ja) 2009-02-23 2016-04-01 プロトンポンプ阻害剤を含む制御放出組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016073927A Pending JP2016164170A (ja) 2009-02-23 2016-04-01 プロトンポンプ阻害剤を含む制御放出組成物

Country Status (5)

Country Link
US (1) US20120128764A1 (enExample)
EP (1) EP2398470A4 (enExample)
JP (2) JP2012518655A (enExample)
CA (1) CA2753444A1 (enExample)
WO (1) WO2010096814A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014189034A1 (ja) * 2013-05-21 2014-11-27 武田薬品工業株式会社 口腔内崩壊錠
JP2016507485A (ja) * 2012-12-04 2016-03-10 サムスン ファイン ケミカルズ カンパニー リミテッドＳａｍｓｕｎｇｆｉｎｅ Ｃｈｅｍｉｃａｌｓ Ｃｏ．，Ｌｔｄ． 積層フィルム及びフィルム積層方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
GB2480773B (en) 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
EP3064217B1 (en) 2009-01-06 2018-04-18 Galenagen, LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
PT3403654T (pt) 2009-10-01 2019-09-05 Adare Dev I L P Composições de corticosteroide administradas oralmente
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
JP5854476B2 (ja) 2009-11-30 2016-02-09 アデア ファーマスーティカルズ，インコーポレイテッド 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法
HU230560B1 (hu) * 2010-07-30 2016-12-28 Péter Hajnal pH-függő szakaszos és nyújtott hatóanyagleadású gyógyszerkészítmény
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
EP3305317B1 (en) 2011-04-21 2020-06-24 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
US10071058B2 (en) * 2012-03-07 2018-09-11 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
HUE042996T2 (hu) 2013-04-23 2019-07-29 Zx Pharma Llc Bélben oldódó bevonatú, fehérjetartalmú alapbevonattal ellátott, több részecskét tartalmazó készítmény
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) * 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
CN112839635A (zh) * 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂
CN109701461B (zh) * 2018-10-25 2021-06-08 西南交通大学 一种基于PEG/Dex双水相的碳酸钙/海藻酸钙复合微囊的制备及其应用
WO2022020464A1 (en) * 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN116674204A (zh) * 2023-05-15 2023-09-01 深圳森工科技有限公司 个性化动物药品3d打印方法、计算机可读存储介质

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62258316A (ja) * 1986-04-30 1987-11-10 Yoshitomi Pharmaceut Ind Ltd 酸不安定物質の内服用新規医薬製剤
JP2003510346A (ja) * 1999-10-04 2003-03-18 ワイス 新規医薬組成物
JP2003192579A (ja) * 2001-10-17 2003-07-09 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
JP2003522141A (ja) * 2000-02-11 2003-07-22 ユーランド ファーマシューティカルズ リミテッド 時限拍動性薬物送達システム
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2006119153A2 (en) * 2005-05-02 2006-11-09 Eurand, Inc. Timed, pulsatile release systems
WO2006118017A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 安定化組成物
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
WO2007090091A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2007093207A1 (de) * 2006-02-18 2007-08-23 Dieter Ramsauer Verspannbare befestigungseinrichtung
WO2008027993A2 (en) * 2006-08-31 2008-03-06 Eurand, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708867A (en) * 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
KR100570446B1 (ko) * 2005-02-14 2006-04-12 지엘팜텍 주식회사 산 불안정성 약리활성물질 함유 장용성 경구용 제제 및 이의 제조방법
EP1988886A1 (en) * 2006-02-13 2008-11-12 Intelgenx Corporation Delayed release pharmaceutical oral dosage form and method of making same
TW200938186A (en) * 2008-02-13 2009-09-16 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62258316A (ja) * 1986-04-30 1987-11-10 Yoshitomi Pharmaceut Ind Ltd 酸不安定物質の内服用新規医薬製剤
JP2003510346A (ja) * 1999-10-04 2003-03-18 ワイス 新規医薬組成物
JP2003522141A (ja) * 2000-02-11 2003-07-22 ユーランド ファーマシューティカルズ リミテッド 時限拍動性薬物送達システム
JP2003192579A (ja) * 2001-10-17 2003-07-09 Takeda Chem Ind Ltd 酸に不安定な薬物の高含量顆粒
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
WO2006118017A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 安定化組成物
WO2006119153A2 (en) * 2005-05-02 2006-11-09 Eurand, Inc. Timed, pulsatile release systems
WO2007090091A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2007093207A1 (de) * 2006-02-18 2007-08-23 Dieter Ramsauer Verspannbare befestigungseinrichtung
WO2008027993A2 (en) * 2006-08-31 2008-03-06 Eurand, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016507485A (ja) * 2012-12-04 2016-03-10 サムスン ファイン ケミカルズ カンパニー リミテッドＳａｍｓｕｎｇｆｉｎｅ Ｃｈｅｍｉｃａｌｓ Ｃｏ．，Ｌｔｄ． 積層フィルム及びフィルム積層方法
WO2014189034A1 (ja) * 2013-05-21 2014-11-27 武田薬品工業株式会社 口腔内崩壊錠
JPWO2014189034A1 (ja) * 2013-05-21 2017-02-23 武田薬品工業株式会社 口腔内崩壊錠
US10004691B2 (en) 2013-05-21 2018-06-26 Takeda Pharmaceuticals Company Limited Orally disintegrable tablet

Also Published As

Publication number Publication date
EP2398470A4 (en) 2013-03-06
EP2398470A1 (en) 2011-12-28
US20120128764A1 (en) 2012-05-24
WO2010096814A1 (en) 2010-08-26
CA2753444A1 (en) 2010-08-26
JP2016164170A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
JP2016164170A (ja) プロトンポンプ阻害剤を含む制御放出組成物
TWI519322B (zh) 包含弱鹼性藥物及控制釋放劑型之組合物
AU2007211091B2 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
JP5845172B2 (ja) 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物
CA2718257C (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP2014501224A (ja) 口腔内崩壊錠
JP2015155441A (ja) 抗コリン薬を具える放出制御組成物
WO2004066924A2 (en) Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2015522653A (ja) プロトンポンプ阻害剤の医薬組成物
KR20070083956A (ko) 양성자 펌프 억제제를 위한 신규 변형 방출 정제 제형
US20090202630A1 (en) Orally disintegrating tablet compositions of ranitidine and methods of manufacture
US20110256218A1 (en) Controlled release compositions comprising meclizine or related piperazine derivatives
WO2011138797A2 (en) Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
MXPA06002443A (es) Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
US20100080846A1 (en) Dipyridamole and acetylsalicylic acid formulations and process for preparing same
JP7584413B2 (ja) 時限式溶出マスキング粒子およびそれを含有する経口医薬組成物
AU2013204408B2 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140901

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141001

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160401

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160930

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161101

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170328